What was the nature of the transaction between Amgen and BeiGene?

Amgen completed a strategic investment in BeiGene by purchasing a significant number of BeiGene American Depositary Shares (ADSs). This was accompanied by a collaboration agreement.

What is the extent of Amgen's ownership in BeiGene following this transaction?

Following the closing, Amgen purchased securities representing up to 20.5% of BeiGene's outstanding share capital.

What is the significance of the Collaboration Agreement?

The Collaboration Agreement, effective as of January 2, 2020, signifies a partnership between Amgen and BeiGene Switzerland GmbH. While the specifics are not detailed in this 8-K, such agreements typically involve co-development, co-commercialization, or other forms of strategic alliance, aiming to leverage the strengths of both companies.

When was this investment initially announced and when did it officially close?

The Share Purchase Agreement was initially entered into on October 31, 2019, and the transaction officially closed on January 2, 2020.

AMGN 8-K: Regulation FD

Summary

Amgen Inc. announced the closing of its strategic investment in BeiGene, Ltd. on January 2, 2020. This transaction, initially disclosed on October 31, 2019, involved Amgen purchasing 15,895,001 BeiGene American Depositary Shares (ADSs), representing a significant equity stake. The investment was made under an amended Share Purchase Agreement that allows Amgen to hold up to 20.5% of BeiGene's outstanding share capital. In conjunction with the equity purchase, Amgen also entered into a Collaboration Agreement with BeiGene Switzerland GmbH, which became effective upon the closing of the share purchase. This collaboration is expected to leverage Amgen's global presence and BeiGene's innovative pipeline, potentially driving future growth and expanding therapeutic offerings for both companies. Investors should monitor the progress and impact of this strategic partnership.

Key Highlights

1Amgen Inc. closed its purchase of 15,895,001 BeiGene American Depositary Shares (ADSs) on January 2, 2020.
2This transaction allows Amgen to hold up to 20.5% of BeiGene's outstanding share capital.
3A Collaboration Agreement between Amgen and BeiGene Switzerland GmbH became effective concurrently with the closing.
4The Share Purchase Agreement was amended on December 6, 2019, to facilitate the investment.
5The investment was initially disclosed on October 31, 2019.
6The press release announcing the closing was issued on January 2, 2020.

AMGEN INC 8-K Report, Regulation FD Disclosure (Jan 2, 2020)

Summary

Key Highlights

Frequently Asked Questions